**Supplementary Tables**

**Disparities between Asian and non-Asian thrombolyzed acute ischemic stroke patients in the ENCHANTED trial**

Chen Chen1,2,3, Xia Wang2, Xiaoying Chen2, Menglu Ouyang2, Lingli Sun3, Hisatomi Arima2,4, Thompson Robinson5, Richard I Lindley2,6, John Chalmers2, Gang Li1\*, Lili Song2,3\*, Craig S Anderson2,3,6,7, for the ENCHANTED Investigators

1Department of Neurology, East Hospital, Tongji University, Shanghai, China

2The George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, Australia

3The George Institute for Global Health at Peking University Health Science Center, Beijing, China

4Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka, Japan

5Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK

6Sydney Medical School, University of Sydney, Sydney, Australia

7Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia

**Table S1. Recruitment countries and patient numbers.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Country** | **rt-PA Arm** | **Blood Pressure Arm** | **Recruitment**  |
| East-Asia |  |  |  |
|  Mainland China  | 1416 | 1428 | 2175 |
|  Hong Kong Area | 7 | 2 | 7 |
|  Taiwan Area | 56 | 16 | 61 |
|  Singapore | 25 | 16 | 33 |
|  Thailand | 1 | 1 | 2 |
|  India | 0 | 35 | 35 |
|  Korea | 353 | 0 | 353 |
|  Vietnam | 221 | 156 | 353 |
| Others |  |  |  |
|  Australia | 52 | 13 | 57 |
|  Italy | 55 | 30 | 65 |
|  United Kingdom | 774 | 259 | 970 |
|  Spain | 0 | 4 | 4 |
|  Chile | 122 | 54 | 136 |
|  Brazil | 191 | 175 | 291 |
|  Norway | 2 | 0 | 2 |
|  Colombia | 11 | 6 | 13 |

**Table S2. Symptomatic intracerebral hemorrhage (sICH) within 7 days, by different criteria**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Non-Asian** | **East-Asian** | **P value** |
| SITS-MOST1 criteria | 25/1574 (1.6) | 46/2977 (1.5) | 0.9111 |
| NINDS2 criteria | 102/1574 (6.5) | 211/2977 (7.1) | 0.4412 |
| ECASS23 criteria | 64/1574 (4.1) | 135/2977 (4.5) | 0.4621 |
| ECASS34 criteria | 33/1574 (2.1) | 59/2977 (2.0) | 0.7937 |
| IST35 criteria | 44/1574 (2.8) | 78/2977 (2.6) | 0.7276 |

SITS-MOST=Safe Implementation of Thrombolysis in Stroke-Monitoring Study. NINDS=National Institutes of Neurological Diseases and Stroke. ECASS=European Cooperative Acute Stroke Study. IST=International Stroke Trial.

1 Large or remote parenchymal intracerebral hemorrhage (type 2, defined as >30% of the infarcted area affected by haemorrhage with mass effect or extension outside the infarct) combined with neurological deterioration (≥4 points on the NIHSS) or leading to death within 24–36 h.

2 Any intracerebral hemorrhage associated with neurological deterioration (≥1 point change in NIHSS score) from baseline, or death within 24–36 h.

3 Any intracerebral hemorrhage with neurological deterioration (≥4 points on the NIHSS) from baseline, or death within 24–36 h.

4 Any intracerebral hemorrhage with neurological deterioration (≥4 points increase on the NIHSS) from baseline, or death within 36 h.

5 Either significant intracerebral hemorrhage (local or distant from the cerebral infarct) or significant hemorrhagic transformation of a cerebral infarct on brain imaging with clinically significant deterioration or death within the first 7 days of treatment.